Developer docs
API playgroundTry for free, no card

Search company profiles

NOVA Genomics

Full company profile

uuid000b7qc

Namestring
NOVA Genomics
Legal namestring
NOVA Genomics, LLC
Company typeenum
Private
Founded yearint
2025
Descriptiontext

NOVA Genomics, LLC is a privately held, Virginia-based reproductive genetics laboratory founded in 2025 by Dr. Gary Harton and Cynthia Hudson. The company provides preimplantation genetic testing (PGT) services to IVF clinics and fertility practices, screening embryos created through in vitro fertilization for chromosomal aneuploidy (PGT-A), single-gene monogenic disorders such as cystic fibrosis and sickle cell anemia (PGT-M), and inherited structural chromosomal rearrangements (PGT-SR). The company is positioned as a purpose-built PGT laboratory, designed from the ground up to address what its founders describe as gaps in legacy lab technologies, quality and compliance, and access to advanced reproductive genetic services, particularly for PGT-SR and PGT-M cases involving inherited conditions.

The company's underlying platform is a next-generation sequencing and molecular diagnostics workflow operated out of a CLIA-grade laboratory in Manassas, Virginia. NOVA delivers the three PGT assays through direct B2B relationships with IVF clinics and through a channel partnership with IVF Store, an online IVF marketplace; it complements testing with integrated genetic counseling via Tandem Genetics and patient financing via PatientFi. The clinical team includes Medical Director Dr. Harvey Stern (30+ years in PGT and molecular genetics), Director of Clinical Services Mary Sands (certified genetic counselor, 20+ years in IVF clinic integration), and Director of Laboratory Services Dr. Brian Mariani, supported by lab leads in SNV and CNV workflows and advisors including Dr. Darren K. Griffin, co-developer of Karyomapping.

NOVA generates revenue on a per-test laboratory services basis, charging IVF clinics fees for each PGT-A, PGT-M, or PGT-SR case analyzed. Pricing is not publicly disclosed, and the company has not announced external funding rounds, named enterprise customers, or revenue figures. Operating geographies are limited to the United States, and compliance posture includes HIPAA, CCPA/CPRA, and COPPA. As a sub-ten-person, founder-led 2025 startup, NOVA remains in early commercialization with its competitive position resting on the depth of its clinical team and its purpose-built laboratory architecture rather than on disclosed technological differentiation.

Short descriptiontext

NOVA Genomics is a Virginia-based reproductive genetics laboratory founded in 2025 that provides preimplantation genetic testing (PGT-A, PGT-M, PGT-SR) services to IVF clinics and fertility practices in the United States using next-generation sequencing and molecular diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersManassas, United States
HQ citystring
Manassas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preimplantation genetic testing, reproductive genetic testing, IVF laboratory services, embryo genetic screening, aneuploidy testing services
Industry4 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Reproductive Genetic Testing Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1PGT Laboratory Services
TypeOne Time License
Description

NOVA Genomics generates revenue through laboratory genetic testing services provided to IVF clinics and fertility practices. The company analyzes embryos for chromosomal abnormalities (PGT-A), single-gene disorders (PGT-M), and structural chromosomal rearrangements (PGT-SR), charging per-test fees for each PGT service rendered.

novagenomics.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NOVA Genomics runs a CLIA-certified preimplantation genetic testing (PGT) laboratory that analyzes embryo biopsies created via in vitro fertilization. It offers three tests — PGT-A for chromosomal aneuploidy, PGT-M for monogenic/single-gene disorders, and PGT-SR for structural chromosomal rearrangements — delivered to IVF clinics and fertility practices for use in clinical decision-making.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Expanding access to advanced genetic services for families in need of PGT-SR and PGT-M testing for inherited conditions
Product overview1 text field

NOVA Genomics offers a unified suite of preimplantation genetic testing (PGT) services for embryos created during in vitro fertilization (IVF). The company provides three distinct testing products: PGT-A screens for chromosomal aneuploidies (extra or missing chromosomes), PGT-M diagnoses single-gene disorders such as cystic fibrosis and sickle cell anemia, and PGT-SR detects structural chromosomal rearrangements inherited from parents. These tests are designed to help physicians and patients make informed clinical decisions during the IVF process.

Product and service3 records
1PGT-A (Preimplantation Genetic Testing for Aneuploidy)
CategoryPreimplantation Genetic Testing
Description

A genetic test to screen embryos (created via IVF) for numerical chromosome changes (aneuploidy), such as Down syndrome. It identifies embryos predicted to have the expected complement of chromosomes and is used by IVF physicians for clinical decision-making.

2PGT-M (Preimplantation Genetic Testing for Monogenic Disorders)
CategoryPreimplantation Genetic Testing
Description

A genetic test performed on embryos (created via IVF) to screen for and diagnose inherited variants that cause monogenic (single-gene) disorders such as cystic fibrosis and sickle cell anemia. Used by IVF physicians to inform embryo selection for couples carrying inherited genetic conditions.

3PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements)
CategoryPreimplantation Genetic Testing
Description

A genetic test used during IVF to screen embryos for unbalanced chromosomal structures caused by inherited rearrangements such as translocations or inversions. Used by IVF physicians to identify embryos free of familial structural chromosomal abnormalities.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Tandem Genetics provides expert genetic counseling services seamlessly integrated with NOVA Genomics PGT testing. Through this partnership, clinics have access to experienced telehealth counselors for pre- and post-testing sessions. Genetic counselors provide clear guidance on results and next steps, ensuring patients receive comprehensive support throughout their IVF journey.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

IVF Store is a full-service online IVF marketplace representing the industry's finest products and solutions. Through this partnership, NOVA Genomics PGT services are available alongside IVF Store's comprehensive offerings, giving clinics a single reliable partner for both everyday needs and next-generation genetic testing services.

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Natera is one of the largest commercial providers of PGT-A, PGT-M, and PGT-SR services, operating Empower PGT and other embryo-screening products. It is the most direct head-to-head competitor to NOVA Genomics in the embryo genetic testing category, with deeper commercial scale and longer operating history.

TypeDirect peer
Description

Igenomix is a global PGT laboratory acquired by Vitrolife, providing PGT-A, PGT-M, and PGT-SR plus reproductive genetics services to IVF clinics worldwide. Comparable to NOVA in clinical offering, with significantly broader geographic footprint and established clinic relationships.

3Reprogenetics (CooperSurgical)
TypeDirect peer
Description

Reprogenetics, part of CooperSurgical, is a long-established PGT reference lab offering PGT-A, PGT-M, and PGT-SR. One of the pioneering PGT labs and a direct competitor with strong IVF-clinic distribution through CooperSurgical's network.

4Genesis Genetics
TypeDirect peer
Description

Genesis Genetics is a specialized PGT/MDL laboratory specializing in PGT-M and PGT-SR testing with patented haplotyping methods. Closely comparable to NOVA in offering depth for monogenic and structural rearrangement cases.

TypeBroad incumbent
Description

Invitae (acquired by Labcorp) is a broad genetic testing platform providing carrier screening and reproductive genetics tests adjacent to PGT. A broader incumbent touching the IVF/reproductive genetics ecosystem rather than direct embryo testing.

TypeBroad incumbent
Description

Labcorp is a global diagnostics leader with reproductive and genetic testing offerings and now owns Invitae. A broad incumbent in clinical laboratory services whose size, payer relationships, and recent fertility-focused investments create competitive context for a small PGT startup.

7Sema4
TypeBroad incumbent
Description

Sema4 is a patient-centered health intelligence and genetic testing company offering reproductive and oncology genetic tests. Operates adjacent in reproductive genetics with broader strategic reach than NOVA.

8Progenity
TypeEmerging player
Description

Progenity is a molecular diagnostics company that has commercialized reproductive and prenatal genetic tests with an emerging PGT portfolio. A comparable emerging competitor with overlapping reproductive genetics focus, though narrower in PGT depth than NOVA's pure-play approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NOVA Genomics

Reproductive Genetic Testing Servicesnovagenomics.org

NOVA Genomics is a Virginia-based reproductive genetics laboratory founded in 2025 that provides preimplantation genetic testing (PGT-A, PGT-M, PGT-SR) services to IVF clinics and fertility practices in the United States using next-generation sequencing and molecular diagnostics.

What NOVA Genomics does

NOVA Genomics, LLC is a privately held, Virginia-based reproductive genetics laboratory founded in 2025 by Dr. Gary Harton and Cynthia Hudson. The company provides preimplantation genetic testing (PGT) services to IVF clinics and fertility practices, screening embryos created through in vitro fertilization for chromosomal aneuploidy (PGT-A), single-gene monogenic disorders such as cystic fibrosis and sickle cell anemia (PGT-M), and inherited structural chromosomal rearrangements (PGT-SR). The company is positioned as a purpose-built PGT laboratory, designed from the ground up to address what its founders describe as gaps in legacy lab technologies, quality and compliance, and access to advanced reproductive genetic services, particularly for PGT-SR and PGT-M cases involving inherited conditions.

The company's underlying platform is a next-generation sequencing and molecular diagnostics workflow operated out of a CLIA-grade laboratory in Manassas, Virginia. NOVA delivers the three PGT assays through direct B2B relationships with IVF clinics and through a channel partnership with IVF Store, an online IVF marketplace; it complements testing with integrated genetic counseling via Tandem Genetics and patient financing via PatientFi. The clinical team includes Medical Director Dr. Harvey Stern (30+ years in PGT and molecular genetics), Director of Clinical Services Mary Sands (certified genetic counselor, 20+ years in IVF clinic integration), and Director of Laboratory Services Dr. Brian Mariani, supported by lab leads in SNV and CNV workflows and advisors including Dr. Darren K. Griffin, co-developer of Karyomapping.

NOVA generates revenue on a per-test laboratory services basis, charging IVF clinics fees for each PGT-A, PGT-M, or PGT-SR case analyzed. Pricing is not publicly disclosed, and the company has not announced external funding rounds, named enterprise customers, or revenue figures. Operating geographies are limited to the United States, and compliance posture includes HIPAA, CCPA/CPRA, and COPPA. As a sub-ten-person, founder-led 2025 startup, NOVA remains in early commercialization with its competitive position resting on the depth of its clinical team and its purpose-built laboratory architecture rather than on disclosed technological differentiation.

NOVA Genomics firmographics

Firmographics
Name
NOVA Genomics
Legal name
NOVA Genomics, LLC
Website
https://novagenomics.org
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
NOVA Genomics is a Virginia-based reproductive genetics laboratory founded in 2025 that provides preimplantation genetic testing (PGT-A, PGT-M, PGT-SR) services to IVF clinics and fertility practices in the United States using next-generation sequencing and molecular diagnostics.
Ownership category
akta.pro rank

NOVA Genomics industry classification

Industry
Product category
Reproductive Genetic Testing Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Preimplantation genetic testing
  • Reproductive genetic testing
  • IVF laboratory services
  • Embryo genetic screening
  • Aneuploidy testing services

Where NOVA Genomics is headquartered

Location

Headquarters

HQ city
Manassas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NOVA Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. PGT Laboratory Services: NOVA Genomics generates revenue through laboratory genetic testing services provided to IVF clinics and fertility practices. The company analyzes embryos for chromosomal abnormalities (PGT-A), single-gene disorders (PGT-M), and structural chromosomal rearrangements (PGT-SR), charging per-test fees for each PGT service rendered.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

NOVA Genomics product offering

Product offering

Core offering

NOVA Genomics runs a CLIA-certified preimplantation genetic testing (PGT) laboratory that analyzes embryo biopsies created via in vitro fertilization. It offers three tests — PGT-A for chromosomal aneuploidy, PGT-M for monogenic/single-gene disorders, and PGT-SR for structural chromosomal rearrangements — delivered to IVF clinics and fertility practices for use in clinical decision-making.

Product overview

NOVA Genomics offers a unified suite of preimplantation genetic testing (PGT) services for embryos created during in vitro fertilization (IVF). The company provides three distinct testing products: PGT-A screens for chromosomal aneuploidies (extra or missing chromosomes), PGT-M diagnoses single-gene disorders such as cystic fibrosis and sickle cell anemia, and PGT-SR detects structural chromosomal rearrangements inherited from parents. These tests are designed to help physicians and patients make informed clinical decisions during the IVF process.

Differentiator

Problem solved

Functional benefit

Products and services

  • PGT-A (Preimplantation Genetic Testing for Aneuploidy) A genetic test to screen embryos (created via IVF) for numerical chromosome changes (aneuploidy), such as Down syndrome. It identifies embryos predicted to have the expected complement of chromosomes and is used by IVF physicians for clinical decision-making.
  • PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) A genetic test performed on embryos (created via IVF) to screen for and diagnose inherited variants that cause monogenic (single-gene) disorders such as cystic fibrosis and sickle cell anemia. Used by IVF physicians to inform embryo selection for couples carrying inherited genetic conditions.
  • PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements) A genetic test used during IVF to screen embryos for unbalanced chromosomal structures caused by inherited rearrangements such as translocations or inversions. Used by IVF physicians to identify embryos free of familial structural chromosomal abnormalities.

Quantifiable outcome

  • Expanding access to advanced genetic services for families in need of PGT-SR and PGT-M testing for inherited conditions

Companies that use NOVA Genomics

Customer profile

Segments2 records

Ideal customer profiles1 record

NOVA Genomics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NOVA Genomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • Tandem GeneticscoreStrategic or Co-development PartnerTandem Genetics provides expert genetic counseling services seamlessly integrated with NOVA Genomics PGT testing. Through this partnership, clinics have access to experienced telehealth counselors for pre- and post-testing sessions. Genetic counselors provide clear guidance on results and next steps, ensuring patients receive comprehensive support throughout their IVF journey.
  • IVF StoresupportingChannel Partner/ Reseller/ DistributorIVF Store is a full-service online IVF marketplace representing the industry's finest products and solutions. Through this partnership, NOVA Genomics PGT services are available alongside IVF Store's comprehensive offerings, giving clinics a single reliable partner for both everyday needs and next-generation genetic testing services.

Scale indicators4 records

Expansion highlights5 records

NOVA Genomics competitors and assessment

Company assessment

Direct peers

  • Natera: Natera is one of the largest commercial providers of PGT-A, PGT-M, and PGT-SR services, operating Empower PGT and other embryo-screening products. It is the most direct head-to-head competitor to NOVA Genomics in the embryo genetic testing category, with deeper commercial scale and longer operating history.
  • Igenomix (Vitrolife): Igenomix is a global PGT laboratory acquired by Vitrolife, providing PGT-A, PGT-M, and PGT-SR plus reproductive genetics services to IVF clinics worldwide. Comparable to NOVA in clinical offering, with significantly broader geographic footprint and established clinic relationships.
  • Reprogenetics (CooperSurgical): Reprogenetics, part of CooperSurgical, is a long-established PGT reference lab offering PGT-A, PGT-M, and PGT-SR. One of the pioneering PGT labs and a direct competitor with strong IVF-clinic distribution through CooperSurgical's network.
  • Genesis Genetics: Genesis Genetics is a specialized PGT/MDL laboratory specializing in PGT-M and PGT-SR testing with patented haplotyping methods. Closely comparable to NOVA in offering depth for monogenic and structural rearrangement cases.

Broad incumbents

  • Invitae (now part of Labcorp): Invitae (acquired by Labcorp) is a broad genetic testing platform providing carrier screening and reproductive genetics tests adjacent to PGT. A broader incumbent touching the IVF/reproductive genetics ecosystem rather than direct embryo testing.
  • Labcorp: Labcorp is a global diagnostics leader with reproductive and genetic testing offerings and now owns Invitae. A broad incumbent in clinical laboratory services whose size, payer relationships, and recent fertility-focused investments create competitive context for a small PGT startup.
  • Sema4: Sema4 is a patient-centered health intelligence and genetic testing company offering reproductive and oncology genetic tests. Operates adjacent in reproductive genetics with broader strategic reach than NOVA.

Emerging players

  • Progenity: Progenity is a molecular diagnostics company that has commercialized reproductive and prenatal genetic tests with an emerging PGT portfolio. A comparable emerging competitor with overlapping reproductive genetics focus, though narrower in PGT depth than NOVA's pure-play approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NOVA Genomics compliance and trust

Trust signal

Compliance3 records

NOVA Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NOVA Genomics leadership team

Management profile

Number of profiles

Profiles7 records

NOVA Genomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NOVA Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOVA Genomics

What does NOVA Genomics do?

NOVA Genomics runs a CLIA-certified preimplantation genetic testing (PGT) laboratory that analyzes embryo biopsies created via in vitro fertilization. It offers three tests — PGT-A for chromosomal aneuploidy, PGT-M for monogenic/single-gene disorders, and PGT-SR for structural chromosomal rearrangements — delivered to IVF clinics and fertility practices for use in clinical decision-making.

Is NOVA Genomics a public or private company?

NOVA Genomics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NOVA Genomics founded?

NOVA Genomics was founded in 2025. It employs 1 to 10 people.

Where is NOVA Genomics based?

NOVA Genomics is headquartered in Manassas, United States, in the North America region.

How does NOVA Genomics make money?

One revenue line is on record: PGT Laboratory Services.

Who are NOVA Genomics's main competitors?

Direct peers on record are Natera, Igenomix (Vitrolife), Reprogenetics (CooperSurgical) and Genesis Genetics. Broad incumbents are Invitae (now part of Labcorp), Labcorp and Sema4. Progenity is listed as an emerging player.

Does NOVA Genomics have an API?

No public API is recorded for NOVA Genomics.

What industry is NOVA Genomics in?

NOVA Genomics's product category is Reproductive Genetic Testing Services. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales